In an EOC preclinical model, TH1 cells produced high levels of CCL5, enabling the recruitment and activation of DC in the tumor microenvironment, which eventually induces tumor-specific CD8+ T-cell activation [46]. The gene discussed is CCL5; the disease is neoplasm.